← Back to screener

MYRIAD GENETICS INC MYGN

Rank #1656 · Nasdaq · $0.6B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
44.8
P/E
-2.3
P/B
0.68
ROE
-29.7%
Op. Margin
-34.2%
Debt Ratio
37%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆
Average

P/E -2.3x, P/B 0.68x. Ranks in the top 52% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -29.7%. Ranks in the top 84% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 37%. Ranks in the top 19% of the universe. Under 100% is generally considered a safe level.

Growth ★★★☆☆
Good

Revenue growth of 11.0% year over year. Ranks in the top 33% of the universe.

Safety is the relative strength · Profitability is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011$0.3B$0.1B$0.1B$0.4B38.79
2012$0.4B$0.1B$0.2B$0.4B37.210
2013$0.4B$0.2B$0.1B$0.6B39.210
2014$0.5B$0.2B$0.1B$0.6B36.413
2015$0.6B$0.2B$0.1B$0.6B37.216
2016$0.8B$0.3B$0.2B$0.7B35.314
2017$0.7B$0.1B$0.1B$0.7B18.618
2018$0.7B$0.1B$0.1B$0.7B18.567
2019$0.7B$0.0B$0.0B$1.0B6.022
2020$0.7B$0.1B$0.1B$1.1B16.444
2021$0.9B$0.0B$0.0B$0.9B0.961
2022$0.6B$-0.2B$-0.2B$1.0B-36.336
2023$0.7B$-0.2B$-0.0B$0.9B-27.636
2024$0.7B$-0.1B$-0.1B$1.0B-20.738
2025$0.8B$-0.3B$-0.3B$0.9B-34.237

← See the full screener